F7 Antibody

說明書

中文名稱：

F7兔多克隆抗體
貨號：

CSB-PA960978
規格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA960978(F7 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using CSB-PA960978(F7 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P08709
基因名：

F7
別名：

coagulation factor VII (serum prothrombin conversion accelerator) antibody; Coagulation factor VII antibody; Eptacog alfa antibody; F7 antibody; FA7_HUMAN antibody; Factor VII antibody; Factor VII heavy chain antibody; Factor VII light chain antibody; FVII coagulation protein antibody; OTTHUMP00000018733 antibody; OTTHUMP00000018734 antibody; Proconvertin antibody; Serum prothrombin conversion accelerator antibody; SPCA antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Fusion protein of Human F7
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:5000
IHC	1:15-1:50

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.
基因功能參考文獻：
1. TF-FVIIa/trypsin-mediated PAR2 activation leads to enhanced MMP-2 expression in human breast cancer cells contributing to tumor progression. PMID: 29870887
2. The current meta-analysis suggested that polymorphism of R353Q in factor VII was not associated with the MI risk. PMID: 30278561
3. The obtained results suggest a possible protective role of Gln353 and -122C alleles in Recurrent Miscarriage. PMID: 27504943
4. FVIIa-antithrombin levels in early and late preeclampsia PMID: 28887028
5. model predicts that small vesicles promote activation of FX by the extrinsic tenase (VIIa/TF) significantly better than large vesicles PMID: 28935233
6. Low levels of FVII:C and FVIIa reflected the degree of consumption of the coagulation factor among paediatric sepsis patients with disseminated intravascular coagulation. PMID: 28492702
7. Report a good correlation between the type of F7 mutation and/or polymorphisms and FVII:C levels, without a direct link between FVII:C and bleeding tendency in factor VII deficiencies. PMID: 28447100
8. Polymorphism rs6046 of the FVII gene is associated with the development of fetal growth retardation in Central Russia. PMID: 28544373
9. A common pathogenic mechanism, possibly a defective folding of the mutant proteins, was triggered by the FVII mutations. The misfolded state led to impaired trafficking of these proteins causing Endoplasmic reticulum retention, which would explain the low to very low FVII plasma levels observed in patients carrying these mutations. PMID: 29246447
10. FVIIa-antithrombin but not FVIIa is a ligand for LRP1, and LRP1 contributes to the clearance of FVIIa-antithrombin in vivo PMID: 27614059
11. heterozygotes for FVII deficiency show rare bleeding manifestations which are also present in the unaffected family members with normal FVII levels. This indicates that Factor VII activity levels played no role in the occurrence of the bleeding symptoms. Furthermore, FVII levels of around 0.40 IU/dl are capable of assuring a normal hemostasis. PMID: 28176610
12. plasma FVIIa-AT has a thrombophilic role in total and cardiovascular mortality risk in patients with clinically stable stable coronary artery PMID: 27061056
13. Family-based association study revealed that the G allele of Protein Z rs2273971, and haplotypes GA, CG, and CGA of Protein Z and factor VII had a significant effect on cerebral hemorrhage susceptibility. PMID: 27350683
14. Our study findings suggest a link between FVII and AR in prostate cancer pathogenesis. PMID: 27434295
15. Suggest that the hemostatic effect of pharmacological doses of rFVIIa in antibody-induced hemophilia mice stems from a TF-independent mechanism PMID: 26727350
16. Large deletions play a minor but essential role in the mutational spectrum of the F7 and F10 genes. Copy number analyses (e. g. MLPA) should be considered if sequencing cannot clarify the underlying reason of an observed coagulopathy. Of note, in cases of combined FVII/FX deficiency, a deletion of the two contiguous genes might be part of a larger chromosomal rearrangement. PMID: 26540129
17. Holders of the R allele had significantly higher activity of coagulation factor F7 (97.66 +/- 15.48 against 83.37 +/- 15.16, p = 0.002) and factor F2 (107.45 +/- 6.03 against 103.75 +/- 6.81, p = 0.023) than holders of the Q allele PMID: 27215039
18. The aim of the study was to evaluate the molecular basis behind low levels of FVII activity (FVII:C) levels in a cohort of Brazilian patients. PMID: 25828579
19. Decreased plasma levels of FVIIa in patients with deep vein thrombosis may indicate ongoing consumption of FVIIa and suggest a contributory role for TF in venous thrombus formation. PMID: 25891834
20. The story of FVII well summarizes the efforts of both theoretical and clinical approaches in the characterization of a coagulation disorder, that is, among the rare bleeding conditions, most frequently encountered in clinical practice. PMID: 25973586
21. Identified are the FVII gene mutations in the Chinese Han population of four unrelated FVII-deficient patients, and the effect of these mutations on the function of FVII molecule level has also been elucidated. PMID: 25767893
22. Letter: large volume of distribution of rFVIIa explains the persistence of some clotting potential when FVII:C is no longer detectable in plasma of patients with inherited FVII deficiency. PMID: 24763923
23. Structural differences in the carboxyl-terminus between the inherited FVII and the therapeutic molecules contributed to the immune response. A naturally-occurring, poorly secreted and 5-residue truncated FVII (FVII-462X) escaped inhibition. PMID: 25104096
24. Polymorphism R353Q (coagulation factor VII) does not represent a protective or risk factor for acute myocardial infarction in young Mexican individuals PMID: 25393858
25. Two heterozygous mutations of F7, g.11349G>A and g.11482T>G, is associated with hereditary coagulation factor deficiency. PMID: 25863091
26. factor VIIa improved heat intolerance by attenuating hypothalamic neuronal apoptosis and damage. PMID: 25033928
27. Results show that the conformational allosteric activation signal extends to the EGF1 domain in the light chain of factor VIIa (FVIIa). PMID: 25344622
28. F7-323Ins10 was associated with lower factor VII levels, but not with individual intraventricular hemorrhage risk in preterm infants. PMID: 25179312
29. Decanucleotide insertion polymorphism of factor VII significantly influences the risk of thrombosis in patients with essential thrombocythemia. PMID: 24617727
30. High Coagulation factor VII expression is associated with breast cancer. PMID: 25447311
31. Persistently high levels of factor VII is associated with insulin resisitance. PMID: 24344794
32. The variability in Factor VII throughout the menstrual cycle in premenopausal women is no greater than for postmenopausal women or men. PMID: 24382103
33. The obtained results suggest a probable protective role of -323P10 allele against the risk of miscarriage in women with > or = 3 recurrent pregnancy losses. PMID: 25219139
34. plasma level is associated with ischemic stroke subtypes PMID: 24048512
35. Results suggest no association between R353Q polymorphism for factor VII and the presence or progression of coronary artery disease in the Iranian population. PMID: 24469878
36. Identification of a homozygous mutation in exon 8 of coagulation FVII that is responsible for factor VII deficiency in a Chinese pedigree. PMID: 23672839
37. Eight missense mutations were identified on the Factor 7 gene (p.Cys82Tyr, p.Cys322Ser, p.Leu357Phe, p.Thr410Ala, c-57C>T) PMID: 23731332
38. Data indicate that nanobilayers containing phosphatidic acid (PA) bound substantially more of two proteins, factor VIIa and activated protein C, than did equivalent bilayers containing phosphatidylserine (PS). PMID: 23879866
39. Data indicate that the interlaboratory precision was better for normal specimens than for factor VII (FVII) <20 U/dL with a mean coefficient of variation (CV) of 17.2% per specimen. PMID: 23590660
40. Polymorphisms in the coagulation factor VII gene modulate the susceptibility to coronary artery disease in Tunisian Arabs. PMID: 22932775
41. Rab GTPases regulate endothelial cell protein C receptor-mediated endocytosis and trafficking of factor VIIa. PMID: 23555015
42. elevated FVII levels, and the -323P0/10 but not R353Q polymorphism, constitute risk factors for ACS. PMID: 23275237
43. Data indicate that hfVII-LC and hIgG1-Fc can effectively inhibit tumor growth and metastases in SCID mice with tissue factor (TF) over-expressing colon cancer. PMID: 23494077
44. Data suggest that plasma FVIIa-AT complex (coagulation factor VII-antithrombin III) is higher in portal vein thrombosis (PVT; without cirrhosis) than in healthy subjects; no difference in FVIIa-AT complex is observed in cirrhosis with/without PVT. PMID: 22958499
45. Report comprehensive molecular analysis of FVII deficiency affected patients in North Tunisia. PMID: 22873696
46. Prothromin genetic mutatation is one of the risk factor in the development of venous thromboembolism and myocardial infarction. PMID: 23382263
47. glucose deprivation enhanced F7 expression in a mechanism reliant on prior ATF4 upregulation primarily due to increased transcription from the ATF4 gene. PMID: 22848420
48. rs6046A allele in F7 associated with decreased blood pressure levels (PPMID: 22815813
49. Intracellular depletion of GTP results in upregulation of coagulation factor VII. PMID: 23050902
50. functional analysis of lethal factor VII deficiency due to novel mutations in the F7 promoter reveals disruption of HNF4 binding site PMID: 22628013
顯示更多

收起更多
相關疾病：

Factor VII deficiency (FA7D)
亞細胞定位：

Secreted.
蛋白家族：

Peptidase S1 family
組織特異性：

Plasma.
數據庫鏈接：

HGNC: 3544

OMIM: 227500

KEGG: hsa:2155

STRING: 9606.ENSP00000364731

UniGene: Hs.36989

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human